This page has no photos on purpose. A before-and-after picture shows one person on one day under chosen lighting. The trial data show what happened to everyone who was enrolled, including the people whose "after" never made it into an ad.
Out of 100 people, where did they land?
STEP-1 randomized 1,961 adults without diabetes to semaglutide 2.4 mg or placebo, both with lifestyle counseling, for 68 weeks. Subtracting the published thresholds gives the bands below.
| Weight lost by week 68 | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Less than 5% | about 14 in 100 | about 69 in 100 |
| 5% to under 10% | about 17 in 100 | about 20 in 100 |
| 10% to under 15% | about 19 in 100 | about 7 in 100 |
| 15% or more | about 50 in 100 | about 5 in 100 |
The mean loss on semaglutide was 14.9% (15.3 kg), against 2.4% (2.6 kg) on placebo. For a person starting at 100 kg, 14.9% is about 15 kg; for someone at 80 kg it is about 12 kg. That arithmetic is only an illustration of what a percentage means, not a prediction.
The photos you see online almost always come from the top band. The FTC's rules, covered below, exist because that top band is not what most people get.
What can't a before-and-after photo show?
- Which drug. A caption that says "semaglutide" could mean Wegovy, Ozempic, or a compounded version. Compounded semaglutide is not FDA-approved and is made with the drug in Wegovy, not the same product. No compounded program has trial data like STEP-1.
- How long, at what dose. STEP-1's results are at 68 weeks, after 16 weeks of escalation to 2.4 mg. A "12 weeks in" photo is mostly at lower doses.
- What the weight was made of. Weight loss includes fat and some lean tissue. Trials measure that with DXA scans in subgroups; neither a photo nor a bathroom scale can. The STEP-1 abstract does not report body-composition figures, and we do not quote numbers we have not checked against the paper.
- What came after. In STEP-4 (JAMA, 2021), people switched to placebo after 20 weeks regained a mean 6.9% over the next 48 weeks. An "after" photo is a snapshot, not an end state.
- Everything else. Lighting, posture, clothing, time of day, hydration, editing, and whether the person had surgery or other treatment at the same time.
What do the FTC endorsement rules say about weight-loss results?
Under the FTC's Endorsement Guides (16 CFR Part 255), an ad that features a consumer's results is generally taken to mean those results are typical. The FTC's business guidance says that if the advertiser lacks proof that the endorser's experience represents what people will generally achieve, the ad must make clear what the generally expected results are. A vague "results not typical" line is not the same as stating what people generally achieve.
For a GLP-1 program, generally expected results would look like the table above, not like the best photo in the gallery. The FTC's separate rule on consumer reviews, in effect since October 21, 2024, targets fake, bought and suppressed reviews. Our article on whether you can trust GLP-1 telehealth reviews explains how that plays out.
Why does the placebo group matter for photos?
Because 31.5% of STEP-1's placebo group lost at least 5% of their weight with counseling alone. A dramatic photo cannot separate the medicine's effect from diet changes, activity, or other treatment. Only a comparison group can, and that is what a trial has and a photo gallery lacks.
Are compounded semaglutide before-and-after photos different?
They carry an extra problem: the photo implies trial-level results for a product that has none. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, lists claims that a compounded drug is the same as an FDA-approved drug among its red flags for online sellers. A gallery beside a compounded product that quotes Wegovy's trial numbers is borrowing evidence from a different product.
Questions worth asking any program that shows transformations: Was the person paid or given free treatment? Which product did they take, and for how long? What result does the program say is typical? If the answers are not on the page, treat the photo as decoration.
How to read a transformation ad in 30 seconds
- Look for a trial name and week. If the ad cites "up to 15%" or "up to 20%", ask: which trial, which drug, at which week, and is it a mean or a best case?
- Check for a typical-results statement. If the ad shows a person who lost 25% and does not say what most people lose, it is not following the spirit of the FTC guidance.
- Find the product name. "Semaglutide" on a compounded program's page is not Wegovy.
- Look for the money-back fine print. Weight guarantees we have read carry conditions, such as logging weight on schedule and avoiding refill gaps.
What is a realistic goal to discuss with a prescriber?
A realistic conversation starts from the distribution, not the best case. In STEP-1, 5% or more was common (86.4%), 10% or more happened for about two in three, and 15% or more for about half. Health benefits in the trial were measured across the group, including cardiometabolic risk factors and participant-reported physical functioning.
It also helps to know the timeline: escalation takes 16 weeks, the headline result is at 68 weeks, and stopping was followed by regain in STEP-4. Our semaglutide weight loss timeline lays out the checkpoints, and STEP trial results covers each trial's design. For how this site handles claims, see our editorial standards.
Frequently asked questions
What percentage of people lose 15% on semaglutide?
In STEP-1, 50.5% of participants on semaglutide 2.4 mg lost 15% or more of their body weight at week 68, compared with 4.9% on placebo. Participants were adults without diabetes who also received lifestyle counseling. About half of the semaglutide group therefore lost less than 15%, which is worth remembering when an ad presents 15% as normal.
Are before-and-after photos of semaglutide real?
Some are real and some are not, and a photo alone cannot tell you. Even an honest photo shows one person, at one moment, often the best result a company has. It does not tell you the drug, dose, duration, or whether the weight stayed off. The FTC expects advertisers to disclose generally expected results when testimonials are not typical.
Does semaglutide cause muscle loss?
Weight loss from any cause includes some lean tissue as well as fat, and trials measure this with DXA scans in subgroups. We have not verified specific semaglutide body-composition figures against the published papers, so we do not quote them here. Ask your prescriber about protein intake and resistance exercise during treatment.
How much weight did people lose on placebo in STEP-1?
The placebo group lost a mean 2.4% of body weight (2.6 kg) at week 68 with lifestyle counseling alone, and 31.5% of them lost at least 5%. That is a useful reminder that some weight loss in any program comes from the diet and activity support, not only the medication.
Can a GLP-1 program legally show its best results in ads?
It can show real results, but the FTC's Endorsement Guides treat a featured consumer result as a claim of typical results. If the advertiser cannot show the result is representative, the ad should clearly state what people generally achieve. A tiny "results may vary" note is not the disclosure the FTC describes.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002 — abstract read 2026-11-08 (PubMed record); doi 10.1056/NEJMoa2032183
- Rubino D et al. Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414-1425 — abstract read 2026-11-08 (PubMed record)
- FTC: Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR Part 255 — section 255.2 on consumer endorsements; eCFR blocked automated reads on 2026-11-08, wording checked via the FTC guidance below
- 16 CFR Part 255: Guides Concerning the Use of Endorsements and Testimonials (eCFR) — generally expected results disclosure read 2026-11-08
- 16 CFR Part 465: Use of Consumer Reviews and Testimonials (eCFR) — staff guidance dated November 2024; rule effective 2024-10-21; read 2026-11-08